The Board stipulated that the company prior to the first day of listing must publish an approved prospectus and raise at least NOK 48 million of new capital through its planned primary share issue.
The Board authorised the Chief Executive Officer of Oslo Børs to fix the date of the first day of listing, which is to be no later than5 December 2014.
Cortendo AB is a biopharmaceutical company with a strategic focus to be the global leader in developing and commercializing products within Orphan Diseases and Endocrinology Disorders. Cortendo aims to be a frontrunner within cortisol inhibition, with its drug candidate COR-003 in a Phase 3 global clinical trial for the treatment of Cushing’s Syndrome. Cortendo intends to independently commercialize its Orphan/Endocrine assets and partner non-strategic product opportunities, such as diabetes.